James Breitmeyer

James B. Breitmeyer was the founder of Oncternal Therapeutics, Inc., founded in 1997, where the titles held included President, Chief Executive Officer & Director from 2016 to 2025.
Current jobs include Chief Executive Officer at Oncternal Oncology, Inc.; Chief Executive Officer & Director at Altay Therapeutics, Inc. starting in 2026; Director at Rebalance Health, Inc.; Independent Director at Vaxart, Inc. starting in 2026; and Operating Partner at Solve FSHD Holdings Ltd. starting in 2025.
Former jobs include President, Chief Executive Officer & Director at Tokalas, Inc.; President & Chief Executive Officer at The Baim Institute for Clinical Research from 2000 to 2001; Independent Director at Zogenix, Inc. from 2014 to 2022; Independent Director at Otonomy, Inc. from 2018 to 2023; Chief Medical Officer & Vice President at Applied Molecular Evolution, Inc. from 2001 to 2006; President at Bavarian Nordic, Inc.; Executive Vice President at Bavarian Nordic A from 2013 to 2015; Chief Medical Officer & Executive VP-Development at Mallinckrodt Hospital Products, Inc. from 2011 to 2012; Chief Medical Officer at EMD Serono, Inc.; Chief Medical Officer & Senior Vice President at Merck Serono SA; and Chief Medical Officer, Head-R&D at Serono International SA from 1991 to 2000.
Education includes an undergraduate degree from the University of California, Santa Cruz in 1975 and a doctorate from Washington University School of Medicine in 1981.